Antithrombotic therapy in atrial fibrillation: An assessment of compliance with guidelines

New Zealand Medical Journal

Volumn 118, Issue 1208, 2005, Pages

  Nair, Anil ^a   Hazell, Wayne ^a   Sutton, Timothy ^a   Pillai, Sandhya ^a  

^a MIDDLEMORE HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DILTIAZEM; ENOXAPARIN; FLECAINIDE; LOW MOLECULAR WEIGHT HEPARIN; METOPROLOL; SOTALOL; WARFARIN; FIBRINOLYTIC AGENT;

ADULT; AGED; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG UTILIZATION; EMERGENCY WARD; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; STROKE; THROMBOEMBOLISM; CLINICAL PATHWAY; MIDDLE AGED; NEW ZEALAND; RISK FACTOR;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; CRITICAL PATHWAYS; FEMALE; FIBRINOLYTIC AGENTS; GUIDELINE ADHERENCE; HUMANS; MALE; MIDDLE AGED; NEW ZEALAND; PRACTICE GUIDELINES; RETROSPECTIVE STUDIES; RISK FACTORS; THROMBOEMBOLISM;

EID: 17144372625     PISSN: 11758716     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Ruster V, Rydén LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with AF: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and Policy Conferences (Committee to Develop Guidelines of the Management of Patients with Atrial Fibrillation). J Am Coll Cardiol. 2001;38:1231-65.
2. Albers GW, Dalen JE, Laupacis A, et al. Antithrombotic therapy in atrial fibrillation. Chest. 2001;119:194S-206S.
3. Huagui L, Easley A, Barrington W, Windle J. Evaluation and management of atrial fibrillation in the Emergency Department. Emerg Med Clinics of North Am. 1998;16:289-303.
4. Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiological features of chronic atrial fibrillation: the Framingham Study. N Engl J Med. 1982;306:1018-22.
5. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly: the Framingham study. Arch Intern Med. 1987;147:1561-4.
6. Benjamin EJ, Wolf PA, D'Agostino RB, et al. Impact of atrial fibrillation on risk of death: the Framingham Study. Circulation. 1998;98:946-52.
7. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999;131:492-501.
8. AFFIRM Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med.2002;347:1825-33.
9. Chang HJ, Bell JR, Deroo DB, et al. Physician variation in anticoagulating patients with atrial fibrillation. Arch Intern Med. 1990;150:81-4.
10. Stafford RS, Singer DE. National patterns of warfarin use in atrial fibrillation. Arch Intern Med. 1996;156:2537-41.
11. Gilbert EH, Lowenstein SR, Koziol-McLain J, et al. Chart reviews in emergency medicine research: Where are the methods? Ann Emerge Med. 1996;27:305-8.
12. S.L.Jackson, G.M.Peterson, J.H.Vial, et al. Outcomes in management of atrial fibrillation: Clinical trial results can apply in clinical practice. Intern Med J. 2001;31:329-36.
13. Atrial fibrillation investigators. Adjusted dose warfarin versus low intensity fixed dose warfarin plus aspirin for high risk patients with atrial fibrillation. Stroke prevention in atrial fibrillation III randomised clinical trial. Lancet.1996;348:633-8.
14. Bungard TJ, Chali WA, Teo KK, et al. Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med. 2000;160:41-6.
15. Man-Son-Hing M, Laupacis A, O'Connor A, et al. Warfarin for atrial fibrillation: the patient's perspective. Arch Intern Med. 1996;156:1841-8.
16. Frykman V, Beerman B, Rydén L, Rosenqvist M. Management of atrial fibrillation: discrepancy between guideline recommendations and actual practice exposes patients to risk for complication. Eur Heart J. 2001;22:1954-9.
17. Stephan D. Fihn, Catherine M. Callahan, Donald C. Martin et al. The risk for and severity of bleeding complications in elderly patients treated with warfarin. Ann Intern Med. 1996;124:970-9.
18. Beyth RJ, Quinn L, Landefeld CS. A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin. Ann Intern Med. 2000;133:687-95.
19. Weigner NJ, Caulfield TA, Danias PG, et al. Risk for clinical thromboembolism associated with conversion to sinus rhythm in patiens with atrial fibrillation lasting less than 48hours. Ann Intern Med. 1997;126:615-20.
20. Kim M, Decena BF, Bruckman D, Eagle KA. Use patterns of low-molecular weight heparin and the impact on length of stay in patients hospitalised for atrial fibrillation. Am Heart J. 2003;145:665-9.
21. Kim MH, Morady F, Conlon B, et al. A prospective, randomised, controlled trial of an Emergency Department based atrial fibrillation treatment strategy with low-molecular-weight-heparin. Ann Emerg Med. 2002;40:187-92.
22. Koenig BO, Ross MA, Jackson RE. An Emergency Department observation unit protocol for acute-onset atrial fibrillation is feasible. Ann Emerg Med. 2002;39:374-81.
23. Michael JA, Stiell IG, Agarwal S, Mandavia DP. Cardioversion of paroxysmal atrial fibrillation in the Emergency Department. Ann Emerg Med. 1999;33:379-87.
24. The management of people with atrial fibrillation and flutter: New Zealand guidelines group consultation draft [New Zealand Guidelines Group website]. June 2004. Available online. URL: http://www.nzgg.org.nz/guidelines/ dsp_guideline_popup.cfm?&guidelineID=85 Accessed January 2005.